



Firazyr[®] (icatibant) – First-time generic

- On July 16, 2019, [Teva launched](#) an AP-rated generic version of Shire's [Firazyr \(icatibant\)](#) injection.
- Firazyr is approved for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.